Natco Pharma Ltd. (NTCPH) says its sales will jump 62 percent in two years once it starts selling a generic version of Copaxone, a treatment for multiple sclerosis.

The company is likely to receive U.S. Food and Drug Administration approval to make the copy in May next year, Chief Executive Officer Rajeev Nannapaneni said in an interview. Teva Pharmaceutical Industries Ltd. (TEVA), which owns the rights for Copaxone, suffered a setback in July after a U.S. court ruling gave the $4 billion drug less than a year of patent protection.

“The big growth next year is going to come from export of formulations, particularly Copaxone,” Nannapaneni said at his office in the southern city of Hyderabad. The FDA approval “is important. We strongly believe we have a fair chance. It will make us an immensely profitable company.” READ FULL ARTICLE ON BLOOMBERG